Abstract:Polycythemia vera (PV) is the most common myeloproliferative neoplasms (MPNs) characterized by the overproduction of morphologically and functionally normal blood cells. Whereas, the clinical usefulness of JAK2 V617F allele burden is still under investigation. We retrospectively reviewed the clinical parameters and haematologic information of 276 patients with PV, including 247 JAK2 mutated and 29 JAK2 unmutated patients, and 38 patients with idiopathic erythrocytosis in the First Affiliated Hospital of Zhejiang University School of Medicine and the Fourth Affiliated Hospital of Zhejiang University School of Medicine(ChiCTR2200061208). JAK2 V617F allele mutational burden was performed in 183 PV patients by RQ-PCR. The expression of WT1 gene was performed in 28 PV patients .JAK2 mutated PV exhibited higher leukocyte counts[12.4(5.0-36.8)×109/L vs 7.1(4.7-17.1)×109/L, P<0.001], neutrophil counts[11.3(3.9-26.6)×109/L vs 4.4(2.2-6.3)×109/L, P<0.001], monocyte counts[0.7(0.3-2.2)×109/L vs 0.6(0.3-0.9)×109/L, P=0.004], eosinophil counts[0.26(0.02-0.96)×109/L vs 0.12(0.04-0.28)×109/L, P<0.001], basophil counts[0.13(0.01-0.62)×109/L vs 0.05(0.02-0.06)×109/L, P<0.001], red blood cell distribution width values[15.2(12.3-23.1)fL vs 12.4(11.7-15.5)fL, P<0.001], platelet counts[616(153-1436)×109/L vs 230(158-375)×109/L, P<0.001], lactate dehydrogenase values[320(144-547) U/L vs 196(117-261) U/L, P<0.001], onset ages[61(26-89) years vs 52(17-72) years, P=0.003], a higher frequency of splenomegaly(41.3% vs 6.9%, P<0.001), lower body mass index[22.91(15.57-32.58) kg/m2 vs 24.83(19.62-34.90) kg/m2, P=0.019] , lymphocyte counts[1.6(0.8-8.7)×109/L vs 2.2(1.3-3.9)×109/L, P=0.015], mean corpuscular hemoglobin values[30.0(22.2-38.6)pg vs 31.5(28.9-36.8)pg, P=0.008], mean corpuscular hemoglobin concentration values[327(294-362)g/L vs 345(324-361)g/L, P<0.001] and serum cholesterol level[3.81(1.84-6.44) mmol/L vs 5.04(3.67-6.41) mmol/L, P=0.001] than JAK2 unmutated patients. PV patients exhibited higher leukocyte counts[13.8(5.0-36.8)×109/L vs 7.5(3.8-11.3)×109/L, P<0.001], neutrophil counts[10.2(2.2-26.6)×109/L vs 4.8(2.1-7.5)×109/L, P<0.001], monocyte counts[0.7(0.3-2.2)×109/L vs 0.5(0.1-1.0)×109/L, P=0.001], eosinophil counts[0.23(0.02-0.96)×109/L vs 0.12(0.03-0.58)×109/L, P=0.001], basophil counts[0.09(0.01-0.62)×109/L vs 0.04(0-0.12)×109/L, P<0.001], red blood cell distribution width values[14.3(11.7-23.1)fL vs 12.5(11.7-15.4)fL, P<0.001], platelet counts[493(153-1436)×109/L vs 233(137-428)×109/L, P<0.001], lactate dehydrogenase values[294(117-547) U/L vs 203(134-301) U/L, P<0.001], onset ages[60(17-89) years vs 45 (20-83) years, P<0.001], a higher frequency of splenomegaly(37.7% vs 7.9%, P<0.001), lower body mass index[23.11(15.57-34.90) kg/m2 vs 25.97(18.40-39.18) kg/m2, P=0.001], mean corpuscular hemoglobin concentration values[332(294-362)g/L vs 342(314-377)g/L, P<0.001] and serum cholesterol level[4.12(1.84-6.44) mmol/L vs 5.00(2.78-7.83) mmol/L, P=0.001] than idiopathic erythrocytosis patients. Among the 276 PV patients, 183 were measured with JAK2 V617F allele burden. The analysis of spearman rank correlation showed that JAK2 V617F allele burdens were positively correlated with white blood cell counts(r=0.5516, P<0.0001), neutrophil count(r=0.8358, P<0.0001), lactate dehydrogenase levels(r=0.6915, P<0.0001). Moreover, the expression level of WT1 gene was positively correlated with JAK2 V617F allele burden(r=0.6653, P=0.0001), white blood cell counts(r=0.4276, P=0.0184), neutrophil count(r=0.4238, P=0.0220), platelet counts(r=0.3914, P=0.0324) and lactate dehydrogenase levels(r=0.6500, P=0.0001). In conclusion, the JAK2 V617F allele burden and the expression level of WT1 gene were correlated with hematologic parameters and clinical outcomes of PV patients. These two tests are recommended for all patients with PV, irrespective of hemoglobin level. The research was supported by the Key R&D Program of Zhejiang, No. 2022C03137; Public Technology Application Research Program of Zhejiang, China, No. LGF21H080003; the Key Project of Jinhua Science and Technology Plan, China, No. 2020-3-011;the 2019-2022 Key Medical Discipline (Hematology) Fund of Jinhua, China. Correspondence: Jian Huang househuang@zju.edu.cn. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis

Prognostic Value of CALR Vs. JAK2V617F Mutations on Splenomegaly, Leukemic Transformation, Thrombosis, and Overall Survival in Patients with Primary Fibrosis: a Meta-Analysis

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Janus kinase 2 inhibitors in myeloproliferative disorders

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis—insights from a multicenter study

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Clinical Features and Outcomes of Polycythemia Vera Patients with Different JAK2 V617F Mutational Status and Allele Burden

PB2217: REAL-WORLD RESEARCH OF CLINICAL AND HEMATOLOGIC NEOPLASMS RELATED GENETIC MUTATIONS IN 275 POLYCYTHEMIA VERA PATIENTS

Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia

JAK2V617F Mutation and Associated Chromosomal Alterations in Primary and Secondary Myelofibrosis and Post-HCT Outcomes

Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera

Calr Vs. JAK2 Vs. MPL Mutations in the Progression of Philadelphia-Negative Myeloproliferative Neoplasms

Moving toward disease modification in polycythemia vera